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subgroup analysis was to evaluate the clinical outcomes of diabetic
patients treated with BVS as compared to non-diabetic subjects.
METHODS A single center all-comers absorb registry was performed
from oct 2012 to feb 2015. A total of 150 consecutive patients with 182
lesions (246 BVS) were included prospectively. 25 diabetics patients
received BVS for 37 lesions, and 125 non-diabetics patients received
BVS for 145 lesions.
RESULTS The basal characteristics of our population was a male/fe-
male ratio of 115/35, with mean age of 559 years. 15% had a family
history of ischemic heart disease, 73% smoking (27% former smokers),
49% hypertension, 51% Dyslipidemia, 4% had prior ischemic heart
disease and 3% prior PCI. 90% of patients had preserved EF. The
clinical presentation was ACS in 94,6% with MI in 76.5%(n¼115) of
patients(42% NSTEMI, 35 STEMI). 26% had multi-vessel disease. The
most frequently affected artery was the left anterior descending (47%
LAD; 15% Circ; 31% RCA; 2.2% LM). Most of the lesions were B2(59%).
Only a 1.1% were CTO. Pre-dilating and post-dilating lesions were
done in the 59/60%. Intracoronary imaging techniques were per-
formed in 89 patients(49%), 91% were OCT. Regarding the whole
group, during a mean follow-up of 294226 days there were 4.7% of
MACE due to TLR, but with no deaths. There were no big differences
in baseline characteristics between diabetics and non diabetics apart
from diabetic patients were less smokers (64% vs 87%; p¼0.01) and
more hypertensive (72% vs 44%;p¼0.01), dyslipidemic (80% vs
45%;p¼0.001), and more of them had previous history of ischemic
heart disease, previous revascularization (16% vs 1% & 14% vs 0%;
p<0.001) and more use of new antiplatelet agents (68% vs
50%;p¼0,03). They had higher rates of pre-dilation (81% vs 54%;
p¼0.005) probably due to more complex lesions (type B2 and C¼ 59%
vs 34%; p¼0.008) and more calciﬁed lesions (16% vs 6%; p¼0.048).
The number of scaffolds per lesion was higher (>2 BVS in 43% vs 21%;
p¼0.018). Regarding the diabetics subgroup, during a mean follow-up
of 294226 they showed a non signiﬁcant but striking trend toward
more MACE (10.8% vs 3.4%; p¼0.056) and restenosis was higher in the
diabetic subgroup (8% vs 0%; p¼0.005). There were no statistical
differences in stent thrombosis (8% vs 3.4%; p¼0.30) although the
difference is remarkable.
CONCLUSIONS In the present analysis, diabetic patients treated with
BVS trended to have more complex lesions with increased need for
pre-dilatation and implantation of more than one BVS. They showed a
statistically non-signiﬁcant trend toward more MACE, although they
had more use of new antiplatelet agents. Intrastent restenosis was
higher in diabetics.
CATEGORIES CORONARY: Bioresorbable Vascular Scaffolds
TCT-519
Feasibility and performance of everolimus-eluting bioresorbable vascular
scaffolds (BVS) in long lesions (>25 mm): all-comers absorb registry with
mid-term follow-up
Santiago J. Camacho Freire,1 Jessica Roa-Garrido,1 Rosa M. Cardenal,1
Antonio Gomez Menchero,1 Javier Leon Jimenez,1
Francisco J. Landero Garcia,1 Prudencia Gomez Fernandez,1
Jose F. Diaz Fernandez1
1Complejo Hospitalario Juan Ramón Jiménez, Huelva, Spain
BACKGROUND Everolimus eluting ABSORB(tm) bioresorbable
vascular scaffold (BVS) represents a novel approach for PCI with
transient vessel support and drug delivery without the long term
limitations of metallic DES. However, the current use of BVS is still
restricted to non-complex lesions. The aim of this subgroup analysis
was to evaluate the feasibility and performance of BVS in long lesions
(>25 mm).
METHODS A single center all-comers absorb registry was performed
from oct 2012 to feb 2015. A total of 150 consecutive patients with 182
lesions (246 BVS) were included, of whom 36.3% had long lesions (66
lesions), and 63.7% had non-long lesions (116 lesions).
RESULTS The male/female ratio was 115/35, with a mean age of 559
years. 15% had a family history of ischemic heart disease, 73%
smoking (27% former smokers), 49% hypertension, 51% Dyslipidemia,
4% had prior ischemic heart disease and 3% prior PCI. 90% of patients
had preserved EF. The clinical presentation was ACS in 94,6% with MI
in 76.5%(n¼115) of patients(42% NSTEMI, 35 STEMI). 26% had multi-
vessel disease. The most frequently affected artery was the left
anterior descending (47% LAD; 15% Circ; 31% RCA; 2.2% LM). Most of
the lesions were B2 (59%), 36% long lesions (>25 mm). There were
more long lesions in RCA and Marginal branches (p¼0.04). Only a 1.1%
were CTO. Pre-dilatation and post-dilatation was done in the 59/60%.Intracoronary imaging techniques were performed in 89 patients
(49%), 91% were OCT. Regarding the whole group, during a median
follow-up of 294226 days there were 4.7% of MACE due to TLR, but
with no deaths. There were 6 stent thrombosis, in 2 of them was due
to non-adherence. All of them resolved with ACTP balloon or with a
new BVS implant. Regarding the subgroup of patients with long le-
sions compared to non-long lesions patients, there were no differ-
ences in ostium affectation (12% vs 8%;p¼0,44), bifurcation lesion
was present in 24% vs 14%(p¼0,1). Pre-dilatation was more
frequent(70% vs 50%;p¼0,01) and post-dilation also(70% vs
61%;p¼0,25), probably due to more complex lesions (type B2 and C¼
68% vs 32%; p<0.0001) and more calciﬁed lesions (14% vs
5%;p¼0,046). All CTOs were long lesions (p¼0.04). There was higher
number of scaffolds per lesion (>2 BVS in 54% vs 9%;p<0,0001) and
obviously, more overlapping (44.2 vs 8.8%; p<0.001) and there were
differences in the mean length of BVS in mm(40.7 vs
18.2 mm;p<0.001). They presented a higher rate of complications
during the implantation (consist of distal edge dissection with TIMI 3
ﬂow: 13.4 vs 5.8%; p¼0.003). During a mean follow-up of 294226
days there was no differences in MACE between groups (TLR 4.5% vs
3.4%; p¼0.71).
CONCLUSIONS In the present analysis, patients treated with BVS in
long lesions showed more complex lesions with increased procedural
complexity, including acute complications, although they showed a
statistically non-difference MACE and stent thrombosis. Further
studies are needed to conﬁrm these ﬁndings.
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BACKGROUND Bioresorbable vascular scaffolds (BVS) implantation in
selected patients with stable angina has been demonstrated feasible
and safe. However data concerning BVS implantation in the setting of
primary percutaneous coronary intervention (P-PCI) for ST-elevation
myocardial infarction (STEMI) is scarce. Therefore, we report our one-
year experience of STEMI patients treated with BVS.
METHODS From April 1st 2013 to March 30th 2014, BVS (Absorb TM,
Abbott Vascular, Santa Clara, CA, USA) became available at our insti-
tution. Selection of lesions to be treated with BVS was left to the
discretion of the interventional cardiologist. For all patients, clinical,
procedural characteristics and in-hospital outcomes were systemati-
cally and prospectively collected in our interventional database. Over
the study period, 343 patients were treated with P-PCI for STEMI; BVS
were implanted in 56 patients (16%), DES in 166 (48%) and BMS in 121
(35%). Baseline demographics and clinical characteristics of patients
were comparable in BVS and DES groups, allowing comparison of
these two groups.
RESULTS Optimal angiographic result was achieved in 88% of cases in
both groups (100% of angiographic procedural success in both
groups). In-hospital MACE rates (death, myocardial infarction, urgent
PCI) were 0% and 1% in BVS and DES groups, respectively. Acute stent
thrombosis (ST) occurred in one patient treated with DES and in none
of the BVS patients. Per-procedural complications rates (dissection,
no-reﬂow phenomenon, side-branch closure, arrhythmia or emboli-
zation) were 7% in both groups. Prasugrel or ticagrelor were used as
the second dual anti-platelet drug in addition to aspirin in 88% of BVS
cases and in 70% of DES cases (p<0,05). One-year outcome will be
presented.
CONCLUSIONS In our non-randomized series of P-PCI for STEMI,
procedural and in-hospital outcomes of patients treated with BVS
were similar as compared with patients treated with conventional
DES. Use of newer anti-platelet drugs (i.e. ticagrelor or prasugrel) was
more frequent among patients treated with BVS as compared to DES.
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